Mutations of the VHL tumour suppressor gene in renal carcinoma

Identification of the von Hippel-Lindau Disease Tumor Suppressor Gene

Latif, F., Tory, K., Gnarra, J. R., Yao, M., Duh, F.-M. C., Orcutt, M. L., Stackhouse, T. M., Kuzmin, I., Modi, W. S., Geil, L., et al. (1993) · Science · doi:10.1126/science.8493574 · Cited by 2,971

The Results of Radical Nephrectomy for Renal Cell Carcinoma

Robson, C. J., Churchill, B. M., & Anderson, W. D. (1969) · The Journal of Urology · doi:10.1016/s0022-5347(17)62331-0 · Cited by 1,303

Mutations in the RET proto-oncogene are associated with MEN 2A and FMTC

Donis-Keller, H., Dou, S., Chi, D., Carlson, K. M., Toshima, K., Lairmore, T. C., Howe, J. R., Moley, J. F., Goodfellow, P. J., & Wells, S. A. (1993) · Human Molecular Genetics · doi:10.1093/hmg/2.7.851 · Cited by 1,298

Hereditary cancer, oncogenes, and antioncogenes.

Knudson, A. G. (1985) · PubMed · Cited by 1,218

The Results of Radical Nephrectomy for Renal Cell Carcinoma

Robson, C. J., Churchill, B. M., & Anderson, W. D. (2016) · The Journal of Urology · doi:10.1016/j.juro.2016.10.095 · Cited by 1,160

A mutation in the RET proto-oncogene associated with multiple endocrine neoplasia type 2B and sporadic medullary thyroid carcinoma

Hofstra, R. M. W., Landsvater, R. M., Ceccherini, I., Stulp, R. P., Stelwagen, T., Luo, Y., Pasini, B., Höppener, J. W. M., van Amstel, H. K. P., Romeo, G., et al. (1994) · Nature · doi:10.1038/367375a0 · Cited by 1,143

Diseases of the kidney

Strauss, M. B., & Welt, L. G. (1963) · Little, Brown eBooks · Cited by 823

Mutations of the RET proto-oncogene in Hirschsprung's disease

Edery, P., Lyonnet, S., Mulligan, L. M., Pelet, A., Dow, E., Abel, L., Holder, S., Nihoul‐Feketé, C., Ponder, B. A. J., & Münnich, A. (1994) · Nature · doi:10.1038/367378a0 · Cited by 746

Point mutations affecting the tyrosine kinase domain of the RET proto-oncogene in Hirschsprung's disease

Romeo, G., Ronchetto, P., Luo, Y., Barone, V., Seri, M., Ceccherini, I., Pasini, B., Bocciardi, R., Lerone, M., Kääriäinen, H., et al. (1994) · Nature · doi:10.1038/367377a0 · Cited by 698

Specific mutations of the RET proto-oncogene are related to disease phenotype in MEN 2A and FMTC

Mulligan, L. M., Eng, C., Healey, C. S., Clayton, D. G., Kwok, J. B., Gardner, E., Ponder, M. A., Frilling, A., Jackson, C. E., Lehnert, H., et al. (1994) · Nature Genetics · doi:10.1038/ng0194-70 · Cited by 643

In vitroevaluation of dimethane sulfonate analogues with potential alkylating activity and selective renal cell carcinoma cytotoxicity

Mertins, S. D., Myers, T. G., Holbeck, S. L., Medina-Pérez, W. Y., Wang, E., Kohlhagen, G., Pommier, Y. G., & Bates, S. E. (2004) · Molecular Cancer Therapeutics · doi:10.1158/1535-7163.849.3.7 · Cited by 22

Preclinical rationale and clinical efficacy of antiangiogenic therapy and immune checkpoint blockade combination therapy in urogenital tumors

Zhu, N., Weng, S., Wang, J., Chen, J., Yu, L., Fang, X., & Yuan, Y. (2019) · Journal of Cancer Research and Clinical Oncology · doi:10.1007/s00432-019-03044-5 · Cited by 22

Inactivation of BRM/SMARCA2 sensitizes clear cell renal cell carcinoma to histone deacetylase complex inhibitors

Fang, R., Pan, R., Wang, X., Yan, L., Wang, X., Ma, H., Zhou, X., Xia, Q., & Rao, Q. (2020) · Pathology - Research and Practice · doi:10.1016/j.prp.2020.152867 · Cited by 22

Coalescing lessons from oxygen sensing, tumor metabolism, and epigenetics to target VHL loss in kidney cancer

Chakraborty, A. A. (2020) · Seminars in Cancer Biology · doi:10.1016/j.semcancer.2020.03.012 · Cited by 23

Childhood cerebellar hemangioblastoma does not predict germline or somatic mutations in the von Hippel‐Lindau tumor suppressor gene

Fisher, P. G., Tontiplaphol, A., Pearlman, E. M., Duffner, P. K., Hyder, D. J., Stolle, C. A., Vortmeyer, A. O., & Zhuang, Z. (2002) · Annals of Neurology · doi:10.1002/ana.10107 · Cited by 22

INTRINSIC DRUG RESISTANCE IN PRIMARY AND METASTATIC RENAL CELL CARCINOMA

Gamelin, E. C., Mertins, S. D., Regis, J. T., Mickley, L. A., Abati, A. D., Worrell, R., Linehan, W. M., & Bates, S. E. (1999) · The Journal of Urology · doi:10.1097/00005392-199907000-00071 · Cited by 22

Adrenomedullin as a therapeutic target in angiogenesis

Deville, J., Salas, S., Figarella‐Branger, D., Ouafik, L., & Daniel, L. (2010) · Expert Opinion on Therapeutic Targets · doi:10.1517/14728222.2010.522328 · Cited by 22

von Hippel-Lindau disease: recent advances and therapeutic perspectives

Richard, S. (2003) · Expert Review of Anticancer Therapy · doi:10.1586/14737140.3.2.215 · Cited by 23

Preimplantation genetic diagnosis using fluorescent in situ hybridization for cancer predisposition syndromes caused by microdeletions

Vanneste, E., Melotte, C., Debrock, S., D’Hooghe, T., Brems, H., Fryns, J. P., Legius, E., & Vermeesch, J. R. (2009) · Human Reproduction · doi:10.1093/humrep/dep034 · Cited by 22

Lipids as Targets for Renal Cell Carcinoma Therapy

Tanturovska, B. S., Manaila, R., Fabbro, D., & Huwiler, A. (2023) · International Journal of Molecular Sciences · doi:10.3390/ijms24043272 · Cited by 22

Function, mechanism and drug discovery of ubiquitin and ubiquitin-like modification with multiomics profiling for cancer therapy

Jiang, Y., Ni, S., Xiao, B., & Jia, L. (2023) · Acta Pharmaceutica Sinica B · doi:10.1016/j.apsb.2023.07.019 · Cited by 22

The single‐cell evolution trajectory presented different hypoxia heterogeneity to reveal the carcinogenesis of genes in clear cell renal cell carcinoma: Based on multiple omics and real experimental verification

Ma, B., Qin, L., Sun, Z., Wang, J., Tran, L. J., Zhang, J., Ye, F., Liu, Y., & Chen, M. (2023) · Environmental Toxicology · doi:10.1002/tox.24009 · Cited by 21

Prognostic significance of erythropoietin expression in human renal cell carcinoma

Michael, A., Politi, E., Havranek, E. G., Corbishley, C. M., Karapanagiotou, L., Anderson, C. J., Relph, K., Syrigos, K. N., & Pandha, H. (2007) · British Journal of Urology · doi:10.1111/j.1464-410x.2007.06978.x · Cited by 21

15‐LOX‐1 suppression of hypoxia‐induced metastatic phenotype and HIF‐1α expression in human colon cancer cells

Wu, Y., Mao, F., Zuo, X., Moussalli, M. J., Elias, E., Xu, W., & Shureiqi, I. (2014) · Cancer Medicine · doi:10.1002/cam4.222 · Cited by 21

Tumor-Associated Carbonic Anhydrases IX and XII

Ondriskova, E., Debreova, M., & Pastoreková, S. (2015) · Elsevier eBooks · doi:10.1016/b978-0-444-63258-6.00010-x · Cited by 21

Renal cell carcinoma histological subtype distribution differs by age, gender, and tumor size in coastal Chinese patients

Wu, J., Zhang, P., Zhang, G., Wang, H., Gu, W., Dai, B., Zhang, H., Shi, G., Shen, Y., Zhu, Y., et al. (2017) · Oncotarget · doi:10.18632/oncotarget.17894 · Cited by 21

Correlating Immune Cell Infiltration Patterns with Recurrent Somatic Mutations in Advanced Clear Cell Renal Cell Carcinoma

Chakiryan, N. H., Hajiran, A. J., Kim, Y., Aydın, A. M., Zemp, L. W., Katende, E. N., Nguyen, J. V., Fan, W., Cheng, C., Lopez-Blanco, N., et al. (2021) · European Urology Focus · doi:10.1016/j.euf.2021.04.014 · Cited by 22

Associations between VHL genotype and clinical phenotype in familial von Hippel–Lindau disease

Huang, J.-S., Huang, C., Chen, S. K., Chien, C., Chen, C. W., & Lin, C. (2007) · European Journal of Clinical Investigation · doi:10.1111/j.1365-2362.2007.01806.x · Cited by 21

Spontaneous Renal Tubular Carcinoma in Fischer-344 Rat Littermates

Thurman, J. D., Hailey, J. R., Turturro, A., & Gaylor, D. W. (1995) · Veterinary Pathology · doi:10.1177/030098589503200412 · Cited by 21

Two regions of homozygosity on chromosome 3p in squamous cell carcinoma of the head and neck: Comparison with cytogenetic analysis

Buchhagen, D. L., Worsham, M. J., Dyke, D. L. V., & Carey, T. E. (1996) · Head & Neck · doi:10.1002/(sici)1097-0347(199611/12)18:6 · Cited by 21

Somatic mutations of the von Hippel-Lindau disease gene in renal carcinomas occurring in patients with long-term dialysis

Inoue, H., Nonomura, N., Kojima, Y., Shiba, M., Oka, D., Arai, Y., Nakayama, M., Takayama, H., Nishimura, K., Mori, H., et al. (2007) · Nephrology Dialysis Transplantation · doi:10.1093/ndt/gfm184 · Cited by 21

Mammalian Target of Rapamycin Inhibitors in Renal Cell Carcinoma: Current Status and Future Applications

Pantuck, A., THOMAS, G. V., Belldegrun, A. S., & Figlin, R. A. (2006) · Seminars in Oncology · doi:10.1053/j.seminoncol.2006.06.002 · Cited by 21

Overexpression of Integrin–associated Protein (CD47) in Rat Kidney Treated with a Renal Carcinogen, Ferric Nitrilotriacetate

Nishiyama, Y., Tanaka, T. U., Naitoh, H., Mori, C., Fukumoto, M., Hiai, H., & Toyokuni, S. (1997) · Japanese Journal of Cancer Research · doi:10.1111/j.1349-7006.1997.tb00356.x · Cited by 21

New Treatments for Renal Cell Carcinoma: Targeted Therapies

Saylor, P. J., & Michaelson, M. D. (2009) · Journal of the National Comprehensive Cancer Network · doi:10.6004/jnccn.2009.0045 · Cited by 21

If Cells Could Talk: The Application of New Techniques to Cytopathology

Abati, A. D., Fetsch, P. A., & Filie, A. C. (1998) · Clinics in Laboratory Medicine · doi:10.1016/s0272-2712(18)30163-x · Cited by 21

Oxygen homeostasis and cancer: insights from a rare disease

Maxwell, P. H. (2002) · Clinical Medicine · doi:10.7861/clinmedicine.2-4-356 · Cited by 21

Fine-needle aspiration of metastatic clear cell carcinoma of the kidney

Beaty, M. W., Zhuang, Z., Park, W. S., Emmert‐Buck, M. R., Linehan, W. M., Lubensky, I. A., & Abati, A. D. (1997) · Cancer · doi:10.1002/(sici)1097-0142(19970625)81:3 · Cited by 21

Molecular Genetics of Renal Cell Carcinoma

Erlandsson, R. (1998) · Cancer Genetics and Cytogenetics · doi:10.1016/s0165-4608(97)00384-1 · Cited by 21

Belzutifan: a novel therapy for von Hippel–Lindau disease

Zhou, J., & Gong, K. (2022) · Nature Reviews Nephrology · doi:10.1038/s41581-022-00544-5 · Cited by 22

Molecular Markers to Predict Response to Therapy

García-Donás, J., Rodríguez‐Antona, C., & Jonasch, E. W. (2013) · Seminars in Oncology · doi:10.1053/j.seminoncol.2013.05.005 · Cited by 20

Pleiotropic Stromal Effects of Vascular Endothelial Growth Factor Receptor 2 Antibody Therapy in Renal Cell Carcinoma Models

Duignan, I. J., Corcoran, E., Pennello, A. L., Plym, M. J., Amatulli, M., Claros, N., Iacolina, M. D., Youssoufian, H., Witte, L., Samakoglu, S., et al. (2011) · Neoplasia · doi:10.1593/neo.101162 · Cited by 20

Cellular milieu in clear cell renal cell carcinoma

Raghubar, A. M., Roberts, M. J., Wood, S., Healy, H. G., Kassianos, A. J., & Mallett, A. J. (2022) · Frontiers in Oncology · doi:10.3389/fonc.2022.943583 · Cited by 20

Effects of point mutations in pVHL on the binding of HIF‐1α

Domene, C., & Illingworth, C. J. R. (2011) · Proteins Structure Function and Bioinformatics · doi:10.1002/prot.23230 · Cited by 20

Pazopanib for the treatment of renal cancer

Rini, B. I., & Al-Marrawi, M. Y. (2011) · Expert Opinion on Pharmacotherapy · doi:10.1517/14656566.2011.571206 · Cited by 20

Tumor VEGF expression correlates with tumor stage and identifies prognostically different groups in patients with clear cell renal cell carcinoma

Minardi, D., Santoni, M., Lucarini, G., Roberta Mazzucchelli, A., Burattini, L., Conti, A., Bianconi, M., Scartozzi, M., Milanese, G., Primio, R. D., et al. (2014) · Urologic Oncology Seminars and Original Investigations · doi:10.1016/j.urolonc.2014.06.014 · Cited by 20

Senescence induction in renal carcinoma cells by Nutlin-3: a potential therapeutic strategy based on MDM2 antagonism

Polański, R., Noon, A. P., Blaydes, J. P., Phillips, A., Rubbi, C. P., PARSONS, K. F., Vlatković, N., & Boyd, M. T. (2014) · Cancer Letters · doi:10.1016/j.canlet.2014.07.024 · Cited by 20

Common reduction of the Raf kinase inhibitory protein in clear cell renal cell carcinoma

Hill, B., Melo, J. D., Yan, J., Kapoor, A., He, L., Cutz, J., Feng, X., Bakhtyar, N., & Tang, D. (2014) · Oncotarget · doi:10.18632/oncotarget.1558 · Cited by 20

Generation and Characterisation of a Pax8-CreERT2 Transgenic Line and a Slc22a6-CreERT2 Knock-In Line for Inducible and Specific Genetic Manipulation of Renal Tubular Epithelial Cells

España, J., Zou, X., Wong, K., Fu, B., Yang, F., Tuveson, D. A., Adams, D. J., & Matakidou, A. (2016) · PLoS ONE · doi:10.1371/journal.pone.0148055 · Cited by 20

Hypoxia signaling and oxygen metabolism in cardio-oncology

Baik, A. H. (2022) · Journal of Molecular and Cellular Cardiology · doi:10.1016/j.yjmcc.2021.12.013 · Cited by 20

Many facets of chromosome 3p cytogenetic findings in clear cell renal carcinoma: the need for agreement in assessment FISH analysis to avoid diagnostic errors.

Brunelli, M., Fiorentino, M., Gobbo, S., Sperandio, N., Liang Cheng, C., Cossu‐Rocca, P., Segala, D., Eble, J. N., Delahunt, B., Novara, G., et al. (2011) · PubMed · doi:10.14670/hh-26.1207 · Cited by 20

Pathologic T1 clear cell renal cell carcinoma: Insulin‐like growth factor‐I receptor expression and disease‐specific survival

Parker, A. S., Cheville, J. C., Blute, M. L., Igel, T. C., Lohse, C. M., & Cerhan, J. R. (2004) · Cancer · doi:10.1002/cncr.20322 · Cited by 20

Genetic disorders and renal cell carcinoma

Maranchie, J. K., & Linehan, W. M. (2003) · Urologic Clinics of North America · doi:10.1016/s0094-0143(02)00120-9 · Cited by 20

Concomitant deregulation of HIF1α and cell cycle proteins in VHL-mutated renal cell carcinomas

Atkins, D., Gingert, C., Justenhoven, C., Schmahl, G. E., Bonato, M., Brauch, H. B., & Störkel, S. (2005) · Archiv für Pathologische Anatomie und Physiologie und für Klinische Medicin · doi:10.1007/s00428-005-1262-y · Cited by 20

Genetic basis of kidney cancer: a model for developing molecular‐targeted therapies

Vira, M. A., Novakovic, K. R., Pinto, P. A., & Linehan, W. M. (2007) · British Journal of Urology · doi:10.1111/j.1464-410x.2007.06814.x · Cited by 20

Analysis of aberrant methylation of the VHL gene by transgenes, monochromosome transfer, and cell fusion

Kuzmin, I., Geil, L., Ge, H., Bengtsson, U., Duh, F.-M. C., Stanbridge, E. J., & Lerman, M. I. (1999) · Oncogene · doi:10.1038/sj.onc.1202959 · Cited by 20

mRNA Expression Profiles of Methylated APAF-1 and DAPK-1 Tumor Suppressor Genes Uncover Clear Cell Renal Cell Carcinomas With Aggressive Phenotype

Christoph, F., Hinz, S., Kempkensteffen, C., Schostak, M., Schrader, M., & Miller, K. (2007) · The Journal of Urology · doi:10.1016/j.juro.2007.07.116 · Cited by 20

[Response to hypoxia. A systemic mechanism based on the control of gene expression].

Caramelo, C. A., Deudero, J. J. P., Castilla, Á., Justo, S., Solís, A. J. D., Neria, F., Peñate, S., & González‐Pacheco, F. R. (2006) · PubMed · Cited by 20

Cellular Respiration and Carcinogenesis

Sarangarajan, R., & Apte, S. (2008) · Humana Press eBooks · doi:10.1007/978-1-59745-435-3 · Cited by 20

Genetics of renal tumours

Fleming, S. (1997) · Cancer and Metastasis Reviews · doi:10.1023/a:1005700508194 · Cited by 20

Molecular genetic analysis of the von Hippel-Lindau and human peroxisome proliferator-activated receptor ? tumor-suppressor genes in adenocarcinomas of the gastroesophageal junction

Wijnhoven, B. P. L., Lindstedt, E. W., Abbou, M., Ijzendoorn, Y., de Krijger, R. R., Tilanus, H. W., & Dinjens, W. N. M. (2001) · International Journal of Cancer · doi:10.1002/ijc.1559 · Cited by 20

HIF2 Inactivation and Tumor Suppression with a Tumor-Directed RNA-Silencing Drug in Mice and Humans

Ma, Y., Joyce, A., Brandenburg, O., Saatchi, F., Stevens, C., Tcheuyap, V. T., Christie, A. L., Do, Q. N., Fatunde, O., Macchiaroli, A., et al. (2022) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-22-0963 · Cited by 21

Modern Therapeutic Approaches in Metastatic Renal Cell Carcinoma

Staehler, M. D., Haseke, N., Schöppler, G., Stadler, T., Gratzke, C., & Stief, C. G. (2006) · EAU-EBU Update Series · doi:10.1016/j.eeus.2006.08.004 · Cited by 19

Renal Cell Carcinoma: Where Will the State-of-the-Art Lead Us?

Brannon, A. R., & Rathmell, W. K. (2010) · Current Oncology Reports · doi:10.1007/s11912-010-0093-4 · Cited by 19

The role of components of the chromatin modification machinery in carcinogenesis of clear cell carcinoma of the ovary (Review)

Shigetomi, H., Onogi, A., Tsunemi, T., Tanase, Y., Yamada, Y., Kajihara, H., Yoshizawa, Y., Furukawa, N., Haruta, S., Yoshida, S., et al. (2011) · Oncology Letters · doi:10.3892/ol.2011.316 · Cited by 19

The pVHL172 isoform is not a tumor suppressor and up-regulates a subset of pro-tumorigenic genes includingTGFB1andMMP13

Hascoët, P., Chesnel, F., Jouan, F., Goff, C. L., Couturier, A., Darrigrand, É., Mahé, F., Rioux-Leclercq, N. C., Goff, X. L., & Arlot‐Bonnemains, Y. (2017) · Oncotarget · doi:10.18632/oncotarget.18376 · Cited by 20

Elevated serum levels of cardiovascular biomarkers are associated with progression of renal cancer

Kamai, T., Tokura, Y., Uematsu, T., Sakamoto, K., Suzuki, I., Takei, K., Narimatsu, T., Kambara, T., Yuki, H., Betsunoh, H., et al. (2018) · Open Heart · doi:10.1136/openhrt-2017-000666 · Cited by 19

Modeling Neoplastic Growth in Renal Cell Carcinoma and Polycystic Kidney Disease

Millet-Boureima, C., He, S., Le, T. B. U., & Gamberi, C. (2021) · International Journal of Molecular Sciences · doi:10.3390/ijms22083918 · Cited by 19

Geospatial Cellular Distribution of Cancer-Associated Fibroblasts Significantly Impacts Clinical Outcomes in Metastatic Clear Cell Renal Cell Carcinoma

Chakiryan, N. H., Kimmel, G. J., Kim, Y., Johnson, J., Clark, N., Hajiran, A. J., Chang, A. C., Aydın, A. M., Zemp, L. W., Katende, E. N., et al. (2021) · Cancers · doi:10.3390/cancers13153743 · Cited by 19

The management of familial breast cancer

Bennett, I., Gattas, M. R., & Teh, B. T. (2000) · The Breast · doi:10.1054/brst.2000.0208 · Cited by 19

Time to disease progression to evaluate a novel protein kinase C inhibitor, UCN‐01, in renal cell carcinoma

Rini, B. I., WEINBERG, V. K., Shaw, V., Scott, J. H., Bok, R., Park, J. W., & Small, E. J. (2004) · Cancer · doi:10.1002/cncr.20313 · Cited by 19

Fragile Histidine Triad (FHIT) Gene and Its Association with p53 Protein Expression in the Progression of Gall Bladder Cancer

Priya, T. P., Kapoor, V. K., Krishnani, N., Agrawal, V., & Agarwal, S. (2009) · Cancer Investigation · doi:10.1080/07357900802711304 · Cited by 19

High Telomerase Activity Correlates with the Stabilities of Genome and DNA Ploidy in Renal Cell Carcinoma

Izumi, H., Hara, T., Oga, A., Matsuda, K., Sato, Y., Naito, K., & Sasaki, K. (2002) · Neoplasia · doi:10.1038/sj.neo.7900205 · Cited by 19

Cytogenetic and molecular analysis of early stage renal cell carcinomas in a family with a translocation (2;3)(q35;q21)

Bodmer, D., Eleveld, M. J., Ligtenberg, M. J. L., Weterman, M. A. J., van der Meijden, A., Koolen, M. I., der Kaa, C. H.-V., Smits, A. P. T., Smeets, D., & van Kessel, A. G. (2002) · Cancer Genetics and Cytogenetics · doi:10.1016/s0165-4608(01)00585-4 · Cited by 19

No Evidence Exists for Methylation Inactivation of thep16Tumor Suppressor Gene in Ovarian Carcinogenesis

Ryan, A., Al-Jehani, R. M., Mulligan, K. T., & Jacobs, I. J. (1998) · Gynecologic Oncology · doi:10.1006/gyno.1997.4881 · Cited by 19

Expression of fibronectin and HIF-1α in renal cell carcinomas: relationship to von Hippel-Lindau gene inactivation

He, Z., Liu, S., Guo, M. Z., Mao, J., & Hughson, M. D. (2004) · Cancer Genetics and Cytogenetics · doi:10.1016/j.cancergencyto.2003.11.001 · Cited by 19

Advances in the molecular basis of renal neoplasia

Cohen, H. T. (1999) · Current Opinion in Nephrology & Hypertension · doi:10.1097/00041552-199905000-00008 · Cited by 19

Inherited epithelial tumors of the kidney: old and new diseases

Zbar, B. (2000) · Seminars in Cancer Biology · doi:10.1006/scbi.2000.0151 · Cited by 19

Hypoxia-inducible factor-2α regulates the expression of TRAIL receptor DR5 in renal cancer cells

Mahajan, S., Dammai, V., Hsu, T., & Kraft, A. S. (2008) · Carcinogenesis · doi:10.1093/carcin/bgn132 · Cited by 20

PDE4D targeting enhances anti-tumor effects of sorafenib in clear cell renal cell carcinoma and attenuates MAPK/ERK signaling in a CRAF-dependent manner

Cao, M., Nawalaniec, K., Ajay, A. K., Luo, Y., Moench, R., Jin, Y., Xiao, S., Hsiao, L., & Waaga-Gasser, A. M. (2022) · Translational Oncology · doi:10.1016/j.tranon.2022.101377 · Cited by 18

Carminomycin I Is an Apoptosis Inducer That Targets the Golgi Complex in Clear Cell Renal Carcinoma Cells

Woldemichael, G. M., Turbyville, T. J., Linehan, W. M., & McMahon, J. B. (2011) · Cancer Research · doi:10.1158/0008-5472.can-10-0757 · Cited by 18

Analysis of renal cell transformation following exposure to trichloroethene in vivo and its metabolite S-(dichlorovinyl)-l-cysteine in vitro

Mally, A., Walker, C. L., Everitt, J. I., Dekant, W., & Vamvakas, S. (2006) · Toxicology · doi:10.1016/j.tox.2006.04.036 · Cited by 18

Expression of hypoxia inducible factor-1α and 2α in conventional renal cell carcinoma with or without sarcomatoid differentiation

Ku, J. H., Park, Y. H., Myung, J. K., Moon, K. C., Kwak, C. H., & Kim, H. H. (2009) · Urologic Oncology Seminars and Original Investigations · doi:10.1016/j.urolonc.2009.08.007 · Cited by 18

Genomic profiling of the genes on chromosome 3p in sporadic clear cell renal cell carcinoma

Togo, Y., Yoshikawa, Y., Suzuki, T., Nakano, Y., Kanematsu, A., Zozumi, M., NOJIMA, M., Hirota, S., Yamamoto, S., & Hashimoto-Tamaoki, T. (2016) · International Journal of Oncology · doi:10.3892/ijo.2016.3395 · Cited by 18

Bisphosphonates and vascular endothelial growth factor-targeted drugs in the treatment of patients with renal cell carcinoma metastatic to bone

Vrdoljak, E., Rini, B. I., Schmidinger, M., Omrčen, T., Torday, L., Szczylik, C. A., & Sella, A. (2013) · Anti-Cancer Drugs · doi:10.1097/cad.0b013e328360335f · Cited by 18

Pazopanib for the Treatment of Patients with Advanced Renal Cell Carcinoma

Lang, J. M., & Harrison, M. R. (2010) · Clinical Medicine Insights Oncology · doi:10.4137/cmo.s4088 · Cited by 18

Gene expression of GLUT isoforms and VHL in oral squamous cell carcinoma

Fukuzumi, M. (2000) · Cancer Letters · doi:10.1016/s0304-3835(00)00613-3 · Cited by 18

Profile of tivozanib and its potential for the treatment of advanced renal cell carcinoma

Cowey, L. (2013) · Drug Design Development and Therapy · doi:10.2147/dddt.s31442 · Cited by 18

Renal Carcinogenesis, Tumor Heterogeneity, and Reactive Oxygen Species: Tactics Evolved

Shanmugasundaram, K., & Block, K. L. (2016) · Antioxidants and Redox Signaling · doi:10.1089/ars.2015.6569 · Cited by 19

Tumor sequencing is useful to refine the analysis of germline variants in unexplained high-risk breast cancer families

van Marcke, C., Helaers, R., Leener, A. D., Merhi, A., Schoonjans, C. A., Ambroise, J., Galant, C., Delrée, P., Rothé, F., Bar, I., et al. (2020) · Breast Cancer Research · doi:10.1186/s13058-020-01273-y · Cited by 18

Blockade of the vascular endothelial growth factor-receptor 2 pathway inhibits the growth of human renal cell carcinoma, RBM1-IT4, in the kidney but not in the bone of nude mice

Karashima, T., Inoue, K., Fukata, S., Iiyama, T., Kurabayashi, A., Kawada, C., & Shuin, T. (2007) · International Journal of Oncology · doi:10.3892/ijo.30.4.937 · Cited by 18

Hepatocyte growth factor-stimulated renal tubular mitogenesis: effects on expression of c-myc, c-fos, c-met, VEGF and the VHL tumour-suppressor and related genes

Clifford, S. C., Czapla, K., Richards, F., O'Donoghue, D. J., & Maher, E. R. (1998) · British Journal of Cancer · doi:10.1038/bjc.1998.235 · Cited by 18

Management of renal cell carcinoma in von Hippel–Lindau disease

Hes, F. J., Slootweg, Vroonhoven, V., Hené, Feldberg, Zewald, van Amstel, P., Höppener, Pearson, & Lips (1999) · European Journal of Clinical Investigation · doi:10.1046/j.1365-2362.1999.00402.x · Cited by 18

The growing family of hereditary renal cell carcinoma

Richard, S., Lidereau, R., & Giraud, S. (2004) · Nephrology Dialysis Transplantation · doi:10.1093/ndt/gfh535 · Cited by 18

HIF-2α downregulation in the absence of functional VHL is not sufficient for renal cell differentiation

Hughes, M. D., Kapllani, E., Alexander, A. E., Burk, R. D., & Schoenfeld, A. R. (2007) · Cancer Cell International · doi:10.1186/1475-2867-7-13 · Cited by 18

Distinct patterns of chromosomal losses in clinically synchronous and asynchronous bilateral renal cell carcinoma.

Kito, H., Suzuki, H., Igarashi, T., Tobe, T., Mizoguchi, K., Kamiya, N., Ichikawa, T., & Itô, H. (2002) · PubMed · doi:10.1016/s0022-5347(05)64234-6 · Cited by 18

Transcription syndromes and the role of RNA polymerase II general transcription factors in human disease.

Aso, T., Shilatifard, A., Conaway, J. W., & Conaway, R. (1996) · Journal of Clinical Investigation · doi:10.1172/jci118580 · Cited by 18

Diagnosis and prognosis of renal-cell tumors: a molecular approach

Wilhelm, M., Krause, U., & Kovács, G. (1995) · World Journal of Urology · doi:10.1007/bf00184868 · Cited by 18

Detection of loss of heterozygosity at chromosome 3p25–26 in primary and metastatic ovarian clear‐cell carcinoma: Utilization of microdissection and polymerase chain reaction in archival tissues

Simsir, A., Palacios, D., Linehan, W. M., Merino, M. J., & Abati, A. D. (2001) · Diagnostic Cytopathology · doi:10.1002/dc.1070 · Cited by 18

Combination therapy in metastatic renal cell carcinoma: Back to the future?

Cerbone, L., Cattrini, C., Vallome, G., Latocca, M. M., Boccardo, F., & Zanardi, E. (2020) · Seminars in Oncology · doi:10.1053/j.seminoncol.2020.10.003 · Cited by 17

Characterization of genetically defined sporadic and hereditary type 1 papillary renal cell carcinoma cell lines

Yang, Y., Ricketts, C. J., Vocke, C. D., Killian, J. K., Padilla‐Nash, H. M., Lang, M., Wei, D., Lee, Y. H., Wangsa, D., Sourbier, C., et al. (2021) · Genes Chromosomes and Cancer · doi:10.1002/gcc.22940 · Cited by 18

Genetics, Pathophysiology, and Current Challenges in Von Hippel–Lindau Disease Therapeutics

Gomez‐Virgilio, L., Velázquez-Paniagua, M., Cuazozon-Ferrer, L., Silva‐Lucero, M., Gutierrez‐Malacara, A., Padilla-Mendoza, J. R., Borbolla‐Vázquez, J., Díaz-Hernández, J. A., Jiménez-Orozco, F. A., & Cárdenas‐Aguayo, M. D. C. (2024) · Diagnostics · doi:10.3390/diagnostics14171909 · Cited by 18

Copy number profiling in von hippel‐lindau disease renal cell carcinoma

Shuib, S., Wei, W., Sur, H., Morris, M. R., McMullan, D. J., Rattenberry, E., Meyer, E., Maxwell, P. H., Kishida, T., Yao, M., et al. (2011) · Genes Chromosomes and Cancer · doi:10.1002/gcc.20865 · Cited by 18

Response Rates and Adverse Effects of Continuous Once-daily Sunitinib in Patients with Advanced Renal Cell Carcinoma: A Single-center Study in Turkey

Yıldız, İ., Şen, F., Başaran, M., Ekenel, M., Ağaoğlu, F., Darendeliler, E., Tunc, H. M., Özcan, F., & Bavbek, S. E. (2011) · Japanese Journal of Clinical Oncology · doi:10.1093/jjco/hyr151 · Cited by 17

Pan-cancer genomic amplifications underlie a WNT hyperactivation phenotype associated with stem cell-like features leading to poor prognosis

Chang, W. H., & Lai, A. G. (2019) · Translational research · doi:10.1016/j.trsl.2019.02.008 · Cited by 17

A transgenic mouse expressing miR‐210 in proximal tubule cells shows mitochondrial alteration: possible association of miR‐210 with a shift in energy metabolism

Nakada, C., Hijiya, N., Tsukamoto, Y., Yano, S., Kai, T., Uchida, T., Kimoto, M., Takahashi, M., Daa, T., Matsuura, K., et al. (2020) · The Journal of Pathology · doi:10.1002/path.5394 · Cited by 17

Identification of anti-tumoral feedback loop between VHLα and hnRNPA2B1 in renal cancer

Liu, Y., Zhang, H., Li, X., Zhang, C., & Huang, H. (2020) · Cell Death and Disease · doi:10.1038/s41419-020-02861-8 · Cited by 17

HIF2α promotes tumour growth in clear cell renal cell carcinoma by increasing the expression of NUDT1 to reduce oxidative stress

Shi, J., Xiong, Z., Wang, K., Yuan, C., Huang, Y., Xiao, W., Meng, X., Chen, Z., Lv, Q., Miao, D., et al. (2021) · Clinical and Translational Medicine · doi:10.1002/ctm2.592 · Cited by 17

Establishment of a Prognostic Prediction and Drug Selection Model for Patients with Clear Cell Renal Cell Carcinoma by Multiomics Data Analysis

Jiang, A., Bao, Y., Wang, A., Gong, W., Gan, X., Wang, J., Bao, Y., Wu, Z., Liu, B., Lü, J., et al. (2022) · Oxidative Medicine and Cellular Longevity · doi:10.1155/2022/3617775 · Cited by 17

Metastatic clear cell carcinoma of the kidney: therapeutic role of bevacizumab

Bukowski, R. M. (2010) · Cancer Management and Research · doi:10.2147/cmar.s7540 · Cited by 17

Non-clear cell advanced kidney cancer

Sánchez, P., Calvo, E., & Durán, I. (2010) · Anti-Cancer Drugs · doi:10.1097/01.cad.0000390767.85658.83 · Cited by 17

Frequent somatic mutations and loss of heterozygosity of the von Hippel-Lindau tumor suppressor gene in primary human renal cell carcinomas.

Shuin, T., Kondo, K., Torigoe, S., Kishida, T., Kubota, Y., Hosaka, M., Nagashima, Y., Kitamura, H., Latif, F., & Zbar, B. (1994) · PubMed · Cited by 471

The role and prognostic significance of the von Hippel-Lindau (VHL) tumor suppressor gene in renal cancer in a South - Western Irish population

Nyhan, M. J., McKenna, S. L., Collins, C. G., Dunne, C. P., Sweeney, P., Rogers, E., & Sullivan, G. C. O. (2005) · Cancer Research

[Frequent somatic mutations of the von Hippel-Lindau (VHL) tumor suppressor gene and its meaning in sporadic human renal clear cell carcinoma].

Gong, K., Zhang, N., Guo, H., Zhang, Z., Xin, D., & Na, Y.-Q. (2004) · PubMed · Cited by 3

Comprehensive mutational analysis of the VHL gene in sporadic renal cell carcinoma: Relationship to clinicopathological parameters

Kondo, K., Yao, M., Yoshida, M., Kishida, T., Shuin, T., Miura, T., Moriyama, M., Kobayashi, K., Sakai, N., Kaneko, S., et al. (2002) · Genes Chromosomes and Cancer · doi:10.1002/gcc.10054 · Cited by 202

Genetics of renal-cell carcinoma and evidence for a critical role for von Hippel-Lindau in renal tumorigenesis.

Gnarra, J. R., Lerman, M. I., Zbar, B., & Linehan, W. M. (1995) · PubMed · Cited by 89